Francescaromana Festuccia1,2, Maryam Tayefeh Jafari3, Alessandra Moioli4,5, Claudia Fofi3,6, Simona Barberi3,6, Stefano Amendola7, Salvatore Sciacchitano8,9, Giorgio Punzo3,6, Paolo Menè3,6. 1. Nephrology and Dialysis Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy. frarom73@yahoo.com. 2. Division of Nephrology, Sant'Andrea University Hospital, Via di Grottarossa 1035-1039, 00189, Rome, Italy. frarom73@yahoo.com. 3. Nephrology and Dialysis Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy. 4. Nephrology and Dialysis Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy. moioli.am@gmail.com. 5. Division of Nephrology, Sant'Andrea University Hospital, Via di Grottarossa 1035-1039, 00189, Rome, Italy. moioli.am@gmail.com. 6. Division of Nephrology, Sant'Andrea University Hospital, Via di Grottarossa 1035-1039, 00189, Rome, Italy. 7. Section of Endocrinology and Diabetology, Ospedale Israelitico, Rome, Italy. 8. Department of Clinical and Molecular Medicine, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy. 9. Laboratory of Biomedical Research, Niccolò Cusano University Foundation, Rome, Italy.
Abstract
BACKGROUND AND AIMS: In elderly subjects, renal insufficiency and osteoporosis often coexist with high risk of fracture and elevated socio-economic burden. Today a large number of effective anti-osteoporotic drugs are available but generally they are contraindicated in patients with chronic kidney disease (CKD) because of their progressive accumulation. Denosumab, instead, does not require dose adjustments for different degrees of renal impairment so it can be a valid treatment in osteoporotic patients with CKD. Limited data are available in the literature concerning the use of denosumab in hemodialysis (HD). The aim of our study was, therefore, to study the efficacy and tolerability of this drug in this particular subset of patients. METHODS: We retrospectively reviewed the charts of 12 osteoporotic HD patients who received a single 60-mg subcutaneous dose of denosumab every 6 months for an observation period of 24 months. Serum electrolyte, markers of bone turnover and quantitative ultrasound (QUS) were evaluated. RESULTS: Over 24 months, we observed a gradual improvement of bone metabolism: β-CrossLaps from 2567.08 ± 1264 to 1492.5 ± 1182.5 pg/ml; bone alkaline phosphatase (BALP) from 33.5 ± 28.8 to 11.8 ± 3.7 mcg/l, and of QUS index (T-score from -5.33 ± 1.58 to -4.84 ± 1.2; risk of fracture from 13.9 ± 4.7 to 11.07 ± 5.3 %). Few cases of hypocalcemia were detected, more significant after the first and second injection, but with careful monitoring of serum calcium and rapid therapy adjustment we could easily manage serum Ca levels. CONCLUSIONS: Our pilot experience highlights the safety and efficacy of denosumab in the treatment of osteoporosis in HD patients, potentially supporting its use to reduce the burden of fractures in this patient population.
BACKGROUND AND AIMS: In elderly subjects, renal insufficiency and osteoporosis often coexist with high risk of fracture and elevated socio-economic burden. Today a large number of effective anti-osteoporotic drugs are available but generally they are contraindicated in patients with chronic kidney disease (CKD) because of their progressive accumulation. Denosumab, instead, does not require dose adjustments for different degrees of renal impairment so it can be a valid treatment in osteoporoticpatients with CKD. Limited data are available in the literature concerning the use of denosumab in hemodialysis (HD). The aim of our study was, therefore, to study the efficacy and tolerability of this drug in this particular subset of patients. METHODS: We retrospectively reviewed the charts of 12 osteoporotic HDpatients who received a single 60-mg subcutaneous dose of denosumab every 6 months for an observation period of 24 months. Serum electrolyte, markers of bone turnover and quantitative ultrasound (QUS) were evaluated. RESULTS: Over 24 months, we observed a gradual improvement of bone metabolism: β-CrossLaps from 2567.08 ± 1264 to 1492.5 ± 1182.5 pg/ml; bone alkaline phosphatase (BALP) from 33.5 ± 28.8 to 11.8 ± 3.7 mcg/l, and of QUS index (T-score from -5.33 ± 1.58 to -4.84 ± 1.2; risk of fracture from 13.9 ± 4.7 to 11.07 ± 5.3 %). Few cases of hypocalcemia were detected, more significant after the first and second injection, but with careful monitoring of serum calcium and rapid therapy adjustment we could easily manage serum Ca levels. CONCLUSIONS: Our pilot experience highlights the safety and efficacy of denosumab in the treatment of osteoporosis in HDpatients, potentially supporting its use to reduce the burden of fractures in this patient population.
Authors: Wojciech P Olszynski; Jonathon D Adachi; David A Hanley; Kenneth S Davison; Jacques P Brown Journal: J Clin Densitom Date: 2015-06-06 Impact factor: 2.617
Authors: Melanie Goldfarb; Stephan S Gondek; Susan M Lim; Josephina C Farra; Vania Nose; John I Lew Journal: World J Surg Date: 2012-06 Impact factor: 3.352
Authors: José Luis Fernández-Martín; Juan Jesus Carrero; Miha Benedik; Willem-Jan Bos; Adrian Covic; Aníbal Ferreira; Jürgen Floege; David Goldsmith; José Luis Gorriz; Markus Ketteler; Reinhard Kramar; Francesco Locatelli; Gérard London; Pierre-Yves Martin; Dimitrios Memmos; Judit Nagy; Manuel Naves-Díaz; Drasko Pavlovic; Minerva Rodríguez-García; Boleslaw Rutkowski; Vladimir Teplan; Christian Tielemans; Dierik Verbeelen; Rudolf P Wüthrich; Pablo Martínez-Camblor; Iván Cabezas-Rodriguez; José Emilio Sánchez-Alvarez; Jorge B Cannata-Andia Journal: Nephrol Dial Transplant Date: 2012-11-19 Impact factor: 5.992
Authors: Jacques P Brown; Richard L Prince; Chad Deal; Robert R Recker; Douglas P Kiel; Luiz H de Gregorio; Peyman Hadji; Lorenz C Hofbauer; Jose M Alvaro-Gracia; Huei Wang; Matthew Austin; Rachel B Wagman; Richard Newmark; Cesar Libanati; Javier San Martin; Henry G Bone Journal: J Bone Miner Res Date: 2009-01 Impact factor: 6.741
Authors: Francesca Tentori; Keith McCullough; Ryan D Kilpatrick; Brian D Bradbury; Bruce M Robinson; Peter G Kerr; Ronald L Pisoni Journal: Kidney Int Date: 2013-07-31 Impact factor: 10.612
Authors: M Abdalbary; M Sobh; S Elnagar; M A Elhadedy; N Elshabrawy; M Abdelsalam; K Asadipooya; A Sabry; A Halawa; A El-Husseini Journal: Osteoporos Int Date: 2022-06-24 Impact factor: 5.071
Authors: J Przedlacki; J Buczyńska-Chyl; P Koźmiński; E Niemczyk; E Wojtaszek; E Gieglis; P Żebrowski; A Podgórzak; J Wściślak; M Wieliczko; J Matuszkiewicz-Rowińska Journal: Osteoporos Int Date: 2018-02-06 Impact factor: 4.507
Authors: C Thongprayoon; P Acharya; C Acharya; J Chenbhanich; T Bathini; B Boonpheng; K Sharma; K Wijarnpreecha; P Ungprasert; M L Gonzalez Suarez; W Cheungpasitporn Journal: Osteoporos Int Date: 2018-04-30 Impact factor: 4.507